Skip to Content


MDS makes every effort to publish accurate information on the website. "Google Translate" is provided as a free tool for visitors to read content in one's native language. Translations are not guaranteed to be 100% accurate. Neither MDS nor its employees assume liability for erroneous translations of website content.

International Parkinson and Movement Disorder Society
Main Content

Past President Lecture Series

MDS Presidential Perspective: A New Approach to the Development of Disease-Modifying Therapies for Parkinson's Disease; Fighting Another Pandemic - presented by: Dr. Warren Olanow

Length:30 MinutesCME Credits:0Release Date:Feb 03, 2021

Experienced / IntermediateExpert / AdvancedPast President Lecture Series

Program Description

The MDS Presidential Perspective: A New Approach to the Development of Disease-Modifying Therapies for Parkinson's Disease; Fighting Another Pandemic course focuses on discussing development of a disease modifying therapy as it is a major unmet therapeutic need in Parkinson's disease. Despite the many promising targets and candidate therapies, many pharmaceutical companies are abandoning this field because of the development costs and regulatory uncertainties. The lecture describes a new approach that Dr. Olanow believes can overcome these problems.


C. Warren Olanow MD, FRCPC, FRCP

Course Purpose

The primary purpose of this webinar is to provide information on a new approach to the development of disease-modifying therapies for Parkinson's disease

Learning Objectives

Upon completion of this activity learners will be able to:

1. Be familiar with obstacles to development of a putative disease modifying therapy for Parkinson's disease

2. Know the clinical designs that have been used to date to try and define a disease modifying therapy

3.Appreciate a new approach to developing disease modifying therapies for Parkinson's disease

Intended Audience

This activity is intended for movement disorder specialists, neurologists, and individuals in the biotech and pharmaceutical industry who are potentially interested in developing disease modifying therapies for Parkinson's disease

Method of Participation

The course must be attended in their entirety. Partial credit is not available. If you are seeking continuing education credit for a specialty not listed in the Accreditation Statement, it is your responsibility to contact your licensing/certification board to determine course eligibility for your board requirement.

Staff Disclosure

MDS staff members involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.

We use cookies to give you the best possible experience with our website. These cookies are also used to ensure we show you content that is relevant to you. If you continue without changing your settings, you are agreeing to our use of cookies to improve your user experience. You can click the cookie settings link on our website to change your cookie settings at any time. Note: The MDS site uses related multiple domains, including and This cookie policy only covers the primary and domain. Please refer to the MDS Privacy Policy for information on how to configure cookies for all other domains on the MDS site.
Cookie PolicyPrivacy Notice